Patients require monitoring for any signs of bleeding, abnormal platelet counts, coagulation parameters, and fibrinogen levels. Patients receiving thrombin-containing products must be monitored for signs of hypersensitive reactions, blood pressure, changes in heart rate, and decrease end-tidal carbon dioxide. Additionally, patients require monitoring for any signs of thromboembolism during and after thrombin has beenÂ administered.